Iron misregulation in the brain: A primary cause of neurodegenerative disorders

Lancet Neurology

Volumn 2, Issue 4, 2003, Pages 246-253

  Ke, Ya ^a   Qian, Zhong Ming ^a,b  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b HEBEI NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CERULOPLASMIN; FERRITIN; IRON; PANTOTHENATE KINASE; POLYPEPTIDE;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; DRUG BRAIN LEVEL; DRUG RELEASE; DRUG STORAGE; DRUG UPTAKE; GENE MUTATION; HALLERVORDEN SPATZ DISEASE; HEREDITY; HUMAN; HUNTINGTON CHOREA; IRON METABOLISM; IRON TRANSPORT; NERVE DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; ANIMAL; BRAIN DISEASE; BRAIN LEVEL; DISEASE MODEL; GENETICS; IRON METABOLISM DISORDER; METABOLISM; MOUSE;

ANIMALS; BRAIN CHEMISTRY; BRAIN DISEASES; DISEASE MODELS, ANIMAL; HUMANS; IRON; IRON METABOLISM DISORDERS; MICE; NEURODEGENERATIVE DISEASES;

EID: 0345714885     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00353-3     Document Type: Review

References (104)

1. Andrews N.C. Medical progress: disorders of iron metabolism. N Engl J Med. 341:1999;1986-1995.
2. Andrews N.C. Iron homeostasis: insights from genetics and animal models. Nat Rev Genet. 1:2000;208-217.
3. Brittenham G.M., Weiss G., Brissot P., et al. Clinical consequences of new insights in the pathophysiology of disorders of iron and heme metabolism. Hematology. 1:2000;39-50.
4. Sheth S., Brittenham G.M. Genetic disorders affecting proteins of iron metabolism: clinical implications. Annu Rev Med. 51:2000;443-464.
5. Roy C.N., Andrews N.C. Recent advances in disorders of iron metabolism: mutations, mechanisms and modifiers. Human Mol Genet. 10:2001;2181-2186.
6. Rouault T.A. Systemic iron metabolism: a review and implications for brain iron metabolism. Pediatr Neurol. 25:2001;130-137.
7. Thompson K.J., Shoham S., Connor J.R. Iron and neurodegenerative disorders. Brain Res Bull. 55:2001;155-164.
8. Youdim M.B. Deficiency and excess of iron in brain function and dysfunction. Nutr Rev. 59:(suppl):2001;S83-S85.
9. Kwok J.C., Richardson D.R. The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol. 42:2002;65-78.
10. Ponting C.P. Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders? Hum Mol Genet. 10:2001;1853-1858.
11. Qian Z.M., Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Rev. 27:1998;257-267.
12. Qian Z.M., Shen X. Brain iron transport and neurodegeneration. Trend Mol Med. 7:2001;103-108.
13. Rouault T.A. Iron on the brain. Nat Genet. 28:2001;299-300.
14. Curtis A.R.J., Fey C., Morris C.M., et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet. 28:2001;350-354.
15. Harrison P.M., Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1275:1996;161-203.
16. Kato J., Fujikawa K., Kanda M., et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet. 69:2001;191-197.
17. Ferreira C., Bucchini D., Martin M.E., et al. Early embryonic lethality of H ferritin gene deletion in mice. J Biol Chem. 275:2000;3021-3024.
18. Swaiman K.F. Hallervorden-Spatz and brain iron metabolism. Arch Neurol. 48:1991;1285-1293.
19. Zhou B., Westaway S.K., Levinson B., Johnson M.A., Gitschier J., Hayflick S.J. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet. 28:2001;345-349.
20. Angelini L., Nardocci N., Rumi V., Zorzi C., Strada L., Savoiardo M. Hallervorden-Spatz disease: clinical and MRI study of 11 cases diagnosed in life. J Neurol. 239:1992;417-425.
21. Swaiman K.F. Hallervorden-Spatz syndrome. Pediatr Neurol. 25:2001;102-108.
22. Hayflick S.J., Penzien J.M., Michl W., Sharif U.M., Rosman N.P., Wheeler P.G. Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol. 25:2001;166-169.
23. Perry T.L., Norman M.G., Yong V.W., et al. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann Neurol. 18:1985;482-489.
24. Heafield M.T., Fearn S., Steventon G.B., Waring R.H., Williams A.C., Sturman S.G. Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease. Neurosci Lett. 110:1990;216-220.
25. Ching K.H., Westaway S.K., Gitschier J., Higgins J.J., Hayflick S.J. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology. 58:2002;1673-1674.
26. Harris Z.L., Takahashi Y., Miyajima H., Serizawa M., MacGillivray R.T., Gitlin J.D. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA. 92:1995;2539-2543.
27. Yoshida K., Furihata K., Takeda S., et al. Mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet. 9:1995;267-272.
28. Harris Z.L., Migas M.C., Hughes A.E., Logan J.I., Gitlin J.D. Familial dementia due to a frameshift mutation in ceruloplasmin gene. Q J Med. 89:1996;355-359.
29. Kaplan J., O'Halloran T.V. Iron metabolism in Eukaryotes: Mars and Venus at it again. Science. 271:1996;1510-1512.
30. Kawanami T., Kato T., Daimon M., et al. Hereditary caeruloplasmin deficiency: clinicopathological study of a patient. J Neurol Neurosurg Psychiatry. 61:1996;506-509.
31. Logan J.I. Hereditary deficiency of ferroxidase (aka caeruloplasmin). J Neurol Neurosurg Psychiatry. 61:1996;431-432.
32. Takahashi Y., Miyajima H., Shirabe S., Nagataki S., Suenaga A., Gitlin J.D. Characterization of a nonsense mutation in the ceruloplasmin gene resulting in diabetes and neurodegenerative diseases. Hum Mol Genet. 5:1996;81-84.
33. Miyajima H., Kohno S., Takahashi Y., Yonekawa O., Kanno T. Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology. 53:1999;617-619.
34. Hellman N.E., Kono S., Miyajima H., Gitlin J.D. Biochemical analysis of a missense mutation in aceruloplasminemia. J Biol Chem. 277:2002;1375-1380.
35. Takeuchi Y., Yoshikawa M., Tsujino T., et al. A case of aceruloplasminaemia: abnormal serum ceruloplasmin protein without ferroxidase activity. J Neurol Neurosurg Psychiatry. 72:2002;543-545.
36. Harris Z.L., Klomp L.W., Gitlin J.D. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr. 67:(suppl 5):1998;S972-S977.
37. Gitlin J.D. Aceruloplasminemia. Pediatr Res. 44:1998;271-276.
38. Osaki S., Johnson D.A., Frieden E. The possible role of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem. 241:1966;11490-11491.
39. Richardson D.R. Role of ceruloplasmin and ascorbate in cellular iron release. J Lab Clin Med. 134:1999;454-465.
40. Gitlin J.D. The sky blue protein. J Lab Clin Med. 134:1999;431-432.
41. Floris G., Medda R., Padiglia A., Musci G. The physiopathological significance of ceruloplasmin: a possible therapeutic approach. Biochem Pharmacol. 60:2000;1735-1741.
42. Hellman N.E., Schaefer M., Gehrke S., et al. Hepatic iron overload in aceruloplasminaemia. Gut. 47:2000;858-860.
43. Hellman N.E., Gitlin J.D. Ceruloplasmin metabolism and function. Annu Rev Nutr. 22:2002;439-458.
44. Harris Z.L., Durley A.P., Man T.K., Gitlin J.D. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA. 96:1999;10812-10817.
45. Mukhopadhyay C.K., Attieh Z.K., Fox A.P. Role of ceruloplasmin in cellular iron uptake. Science. 279:1998;714-717.
46. Attieh Z.K., Mukhopadhyay C.K., Seshadri V., Tripoulas N.A., Fox P.L. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J Biol Chem. 274:1999;1116-1123.
47. Qian Z.M., Tsoi Y.K., Ke Y., Wong M.S. Ceruloplasmin promotes iron uptake rather than release in BT325 cells. Exp Brain Res. 140:2001;369-374.
48. Xie J.X., Tsoi Y.K., Chang Y.Z., Ke Y., Qian Z.M. Effects of ferroxidase activity and species on ceruloplasmin mediated iron uptake by BT325 cells. Mol Brain Res. 99:2002;12-16.
49. Klomp L.W.J., Farhangrazi Z.S., Dugan L.L., Gitlin J.D. Ceruloplasmin gene expression in the murine central nervous system. J Clin Invest. 98:1996;207-215.
50. Klomp L.W.J., Gitlin J.D. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet. 5:1996;1989-1996.
51. Qian Z.M., Ke Y. Rethinking the role of ceruloplasmin in brain iron metabolism. Brain Res Rev. 35:2001;287-294.
52. Miyajima H., Fujimoto M., Kohno S., Kaneko E., Gitlin J.D. CSF abnormalities in patients with aceruloplasminemia. Neurology. 51:1998;1188-1190.
53. Miyajima H., Adachi J., Kohno S., Takahashi Y., Ueno Y., Naito T. Increased oxysterols associated with iron accumulation in the brains and visceral organs of acaeruloplasminaemia patients. Q J Med. 94:2001;417-512.
54. Miyajima H., Takahashi Y., Kono S., et al. Glucose and oxygen hypometabolism in aceruloplasminemia brains. Intern Med. 41:2002;186-190.
55. Yoshida K., Kaneko K., Miyajima H., et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J Neurol Sci. 175:2000;91-95.
56. Miyajima H., Takahashi Y., Kamata T., Shimizu H., Sakai N., Gitlin J.D. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol. 41:1997;404-407.
57. LaVaute T., Smith S., Cooperman S., et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet. 27:2001;209-214.
58. Klausner R.D., Rouault T.A., Harford J.B. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell. 72:1993;19-28.
59. Bonkovsky H., Ponka P., Bacon B.R., Drysdale J., Grace N.D., Tavill A.S. An update on iron metabolism: summary of the fifth international conference on disorders on iron metabolism. Hepatology. 24:1996;718-729.
60. Hentze M.W., Kuhn L.C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA. 93:1996;8175-8182.
61. Hu J., Connor J.R. Demonstration and characterization of the iron regulatory protein in human brain. J Neurochem. 67:1996;838-844.
62. Cairo G., Pietrangelo A. Iron regulatory proteins in pathobiology. Biochem J. 352:2000;241-250.
63. Eisenstein R.S. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr. 20:2000;627-662.
64. Nunez-Millacura C., Tapia V., Munoz P., Maccioni R.B., Nunez M.T. An oxidative stress-mediated positive-feedback iron uptake loop in neuronal cells. J Neurochem. 82:2002;240-248.
65. Roy C.N., Blemings K.P., Deck K.M., et al. Increased IRP1 and IRP2 RNA binding activity accompanies a reduction of the labile iron pool in HFE-expressing cells. J Cell Physiol. 190:2002;218-226.
66. Cairo G., Recalcati S., Pietrangelo A., Minotti G. The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med. 32:2002;1237-1243.
67. Qian Z.M., Li H., Sun H., Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev. 54:2002;561-587.
68. Faucheux B.A., Nillesse N., Damier P., et al. Expression of lactoferrin receptors in increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA. 92:1995;9603-9607.
69. Leveugle B., Spik G., Perl D.P., Bouras C., Fillit H.M., Hof P.R. The iron binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res. 650:1994;20-31.
70. Leveugle B., Faucheux B.A., Bouras C., et al. Cellular distribution of the iron-binding protein lactoferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol. 91:1996;566-572.
71. Jefferies W.A., Gabathuler R., Rotherberger S., Food M., Kennard M.L. Pumping iron in the '90s. Trend Cell Biol. 6:1996;223-228.
72. Kennard M.L., Feldman H., Yamada T., Jefferies W.A. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat Med. 2:1996;1230-1235.
73. Jefferies W.A., Food M.R., Gabathuler R., et al. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res. 712:1996;122-126.
74. Yamada T., Tsujioka Y., Taguchi J., et al. Melanotransferrin is produced by senile plaque-associated reactive microglia in Alzheimer's disease. Brain Res. 845:1999;1-5.
75. Kim D.K., Seo M.Y., Lim S.W., et al. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacology. 25:2001;84-90.
76. Ujiie M., Dickstein D.L., Jefferies W.A. p97 as a biomarker for Alzheimer disease. Front Biosci. 7:2002;e42-e47.
77. Osmand A.P., Switzer R.C. III. Differential distribution of lactoferrin and Alz-50 immunoreactivities in neuritic plaques and neurofibrillary tangles in Alzheimer's disease. Iqbal K., McLachlan R.C., Winblad B., Wisniewski H.M. Alzheimer's disease: basic mechanisms, diagnosis and therapeutic strategies. 1991;219-227 Wiley, New York.
78. Kawamata T., Tooyama I., Yamada T., Walker D.G., McGeer P.L. Lacto-transferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol. 142:1993;1574-1585.
79. Rebeck G.W., Harr S.D., Strickland D.K., Hyman B.T. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha-macroglobulin receptor/low density lipoprotein receptor-related protein. Ann Neurol. 37:1995;211-217.
80. Fleming M.D., Trenor C.C.I., Su M.A., Foemzler D.R., Dietrich W.F., Andrews N.C. Microcytic anemia have a mutation in Nramp2, a candidate iron transporter. Nat Genet. 16:1997;383-386.
81. Gunshin H., Mackenzie B., Berger U.V., et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 388:1997;482-488.
82. Andrews N.C., Fleming M.D., Gunshin H. Iron transport across biological membranes. Nutr Rev. 57:1999;114-123.
83. Torsdottir G., Kristinsson J., Sveinbjornsdottir S., Snaedal J., Johannesson T. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol Toxicol. 85:1999;239-243.
84. Boll M.C., Sotelo J., Otero E., Alcaraz-Zubeldia M., Rios C. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci Lett. 265:1999;155-158.
85. Berg D., Gerlach M., Youdim M.B., et al. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem. 79:2001;225-236.
86. Piñero D.J., Hu J., Connor J.R. Alterations in the interaction between iron regulatory proteins and their responsive element in normal and Alzheimer's diseased brains. Cell Mol Biol. 46:2000;761-776.
87. Yamanaka K., Minato N., Iwai K. Stabilization of iron regulatory protein 2, IRP2, by aluminum. FEBS Lett. 462:1999;216-220.
88. Schipper H.M. Heme oxygenase-1: role in brain aging and neurodegeneration. Exp Gerontol. 35:2000;821-830.
89. Smith M.A., Nunomura A., Zhu X., Takeda A., Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal. 2:2000;413-420.
90. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging. 18:2001;685-716.
91. Loreal O., Turlin B., Pigeon C., et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol. 36:2002;851-856.
92. Perry G., Sayre L.M., Atwood C.S., et al. The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs. 16:2002;339-352.
93. Cash A.D., Perry G., Smith M.A. Therapeutic potential in Alzheimer disease. Curr Med Chem. 9:2002;1605-1610.
94. McKie A.T., Barrow D., Latunde-Dada G.O., et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science. 291:2001;1755-1759.
95. Donovan A., Brownlie A., Zhou Y., et al. Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter. Nature. 403:2000;776-781.
96. Vulpe C.D., Kuo Y.M., Murphy T.L., et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet. 21:1999;195-199.
97. Jiang D.H., Ke Y., Cheng Y.Z., Ho K.P., Qian Z.M. Distribution of ferroportin1 protein in different regions of developing rat brain. Dev Neurosci. 24:2002;94-98.
98. Krause A., Neitz S., Magert H.J., et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480:2000;147-150.
99. Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 276:2001;7806-7810.
100. Nicolas G., Bennoun M., Devaux I., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA. 98:2001;8780-8785.
101. Frazer D.M., Wilkins S.J., Becker E.M., et al. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology. 123:2002;835-844.
102. Nicolas G., Bennoun M., Porteu A., et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA. 99:2002;4596-4601.
103. Fleming R.E., Sly W.S. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA. 98:2001;8160-8162.
104. Fleming R.E., Sly W.S. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu Rev Physiol. 64:2002;663-680.